← Eichor
Condition: Atypical Hyperplasia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Atypical Hyperplasia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
Phase 2/Phase 3 · 1 location(s) · Xiaojun Chen · NCT05316493GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Phase 2/Phase 3 · 2 location(s) · Xiaojun Chen · NCT05316935Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT06195306Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Tre
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07077876Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial H
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT05675787Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT05647109Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Phase N/A · 3 location(s) · Proteocyte Diagnostics Inc. · NCT04622462Intrauterine Injection of Type III Collage in FST of EC/AEH
Phase 2 · 1 location(s) · Wang Jianliu · NCT07377734Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Develop
Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT05941520Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Phase 2 · 11 location(s) · National Cancer Institute (NCI) · NCT06184750Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
NA · 1 location(s) · University Health Network, Toronto · NCT04008563Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied t
Phase N/A · 3 location(s) · Mayo Clinic · NCT06365905High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
Phase N/A · 1 location(s) · Carol Fabian, MD · NCT00291096Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05178498Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial H
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06102863Uterine Preservation Via Lifestyle Transformation
Phase 2 · 3 location(s) · Washington University School of Medicine · NCT05903131Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Phase N/A · 24 location(s) · Mayo Clinic · NCT05051722Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Phase 2/Phase 3 · 1 location(s) · West China Second University Hospital · NCT03463252GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Phase 2/Phase 3 · 2 location(s) · Xiaojun Chen · NCT06379113Endometrial Cancer Vaginal Fluid Specimen Collection Study
Phase N/A · 1 location(s) · Exact Sciences Corporation · NCT07544680Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia
NA · 1 location(s) · Vancouver Coastal Health Research Institute · NCT04362046The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
Phase N/A · 1 location(s) · University of Alabama at Birmingham · NCT03538665Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
Phase N/A · 5 location(s) · Proteocyte Diagnostics Inc. · NCT05853783
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.